Gadolinium based contrast agents (GBCAs) are widely used in medical imaging with 10 million annual doses given in the US alone. There is a very low 0.03% risk of serious adverse reactions. GBCAs were thought entirely safe until 2006 when reports of nephrogenic system fibrosis (NSF) surfaced. NSF was nearly eliminated by 2009 through careful screening and reducing dosage. In 2014, it was reported that GBCAs may deposit in the brains of patients. The purpose of this review is to examine the literature to date. Read More

Meeting name: IPR 2016 Conjoint Meeting & Exhibition , 2016

Authors: Rozenfeld Michael, Garcia Sebastian, Nelson Paige, Burrowes Delilah

Keywords: Brain, Gadolinium